Research programme: G protein-coupled receptor modulators - Alchemia/Ogeda
Latest Information Update: 18 May 2017
At a glance
- Originator Alchemia; Euroscreen
- Developer Alchemia; Ogeda
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Chronic obstructive pulmonary disease; Obesity
- No development reported Diabetes mellitus; Inflammation; Pain; Rheumatoid arthritis
Most Recent Events
- 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
- 19 Oct 2016 Euroscreen is now called Ogeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in Australia